ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
Antidiabetic Effects and Mechanisms of Action of Uncaria gambir Roxb. in Diabetic Sprague-Dawley Rats.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeted Regulation of Pancreatic Islet Function by Natural Products Against Type 2 Diabetes Mellitus: Advances and Prospects.Biomolecules · 2026Review
- Hormetic Antioxidant Effects ofInternational journal of molecular sciences · 2026Article
- Evaluation of acute and sub-acute toxicity ofResearch in pharmaceutical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antidiabetic properties of Uncaria gambir are not yet fully understood, particularly concerning how it affects diabetic animal models. Further investigation in this aspect is pivotal before initiating clinical evaluations. This study aimed to investigate the antidiabetic activity of U. gambir and how it influences blood glucose levels in diabetic Sprague-Dawley rats. In this study, 28 rats were divided into 7 groups. The groups were as follows: a nondiabetic rat group, a nondiabetic rat group given U. gambir, a diabetic rat group, a diabetic rat group given glibenclamide, and 3 diabetic rat groups given U. gambir at 3 doses (200, 300, and 400 mg/kg). Diabetes was induced using streptozotocin (50 mg/kg) given by intraperitoneal injection. Blood glucose levels were measured weekly, and the animals were euthanized at the end of the experiment. Intracardiac blood and tissues such as the pancreas, liver, and skeletal muscle were collected for further analysis. The results showed that administering U. gambir to diabetic rats resulted in significantly lower blood glucose levels than untreated diabetic rats. U. gambir has a complex mechanism to reduce blood glucose levels. including increase of insulin production, preservation of the islets and pancreatic β cells, and optimization of glycogenesis, as reflected in a significant increase in liver glycogen levels. These findings suggest that U. gambir's multicompound and multitarget capabilities in controlling blood glucose levels may have utility for treatment of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.